Vertex Pharmaceuticals Inc/ US92532F1003 /
| 2024-08-26 9:13:13 AM | Chg. - | Volume | Bid5:28:32 PM | Ask5:28:32 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 429.55EUR | - | 3 Turnover: 1,288.65 |
-Bid Size: - | -Ask Size: - | 113.17 bill.EUR | - | - |
Assets
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 698.3620 | 789.4370 | 812.0050 | 758.0850 | 958.5340 | ||||||
| Intangible Assets | 284.3400 | 29 | - | 400 | 400 | ||||||
| Long-Term Investments | 20.2760 | 20.4470 | - | - | - | ||||||
| Fixed Assets | - | 897.0510 | 2,402.7890 | 3,495.6360 | 3,618.4290 | ||||||
| Inventories | 77.6040 | 111.8300 | 124.3600 | 167.5020 | 280.7770 | ||||||
| Accounts Receivable | 201.0830 | 281.3430 | 409.6880 | 633.5180 | 885.3520 | ||||||
| Cash and Cash Equivalents | 1,183.9450 | 1,665.4120 | 2,650.1340 | 3,109.3220 | 5,988.1870 | ||||||
| Current Assets | 1,831.5400 | 2,648.9630 | 3,843.1090 | 4,822.8290 | 8,133.3790 | ||||||
| Total Assets | 2,896.7870 | 3,546.0140 | 6,245.8980 | 8,318.4650 | 11,751.8080 | ||||||
Liabilities
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 61.4510 | 73.9940 | 110.9870 | 87.6100 | 155.1390 | ||||||
| Long-term debt | 521.3350 | 583.9020 | 581.5500 | 538.5760 | 539.0420 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | 134.1000 | 6.3000 | - | - | - | ||||||
| Liabilities | 1,558.5960 | 1,503.7080 | 1,810.6950 | 2,233.2210 | 3,064.9930 | ||||||
| Share Capital | 2.4500 | 2.5120 | 2.5460 | 2.5890 | 2.5990 | ||||||
| Total Equity | 1,338.1910 | 2,042.3060 | 4,435.2030 | 6,085.2440 | 8,686.8150 | ||||||
| Minority Interests | 181.6090 | 13.7270 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Total liabilities equity | 2,896.7870 | 3,546.0140 | 6,245.8980 | 8,318.4650 | 11,751.8080 | ||||||
Income Statement
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,702.1770 | 2,488.6520 | 3,047.5970 | 4,162.8210 | 6,205.6830 | ||||||
| Depreciation (total) | 61.3980 | 61.3970 | 72.4200 | 106.9410 | 109.5150 | ||||||
| Operating Result | 9.9360 | 123.2430 | 635.1500 | 1,197.5660 | 2,856.2900 | ||||||
| Interest Income | 81.4320 | 57.5500 | 34.1190 | - | - | ||||||
| Income Before Taxes | -67.3660 | -15.6890 | 600.2410 | 1,394.9190 | 3,116.7980 | ||||||
| Income Taxes | 16.6650 | -107.3240 | -1,486.8620 | 218.1090 | 405.1510 | ||||||
| Minority Interests Profit | -28.0210 | 171.8490 | 9.7930 | 0.0000 | 0.0000 | ||||||
| Net Income | -112.0520 | 263.4840 | 2,096.8960 | 1,176.8100 | 2,711.6470 | ||||||
Per Share
Cash Flow
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 236.1030 | 844.9420 | 1,270.2860 | 1,569.3300 | 3,253.5050 | ||||||
| Cash Flow from Investing Activities | 104.4690 | -437.6810 | -202.1580 | -1,235.3180 | 99.3880 | ||||||
| Cash Flow from Financing | 133.2710 | 68.4040 | -71.2190 | 126.7730 | -505.2810 | ||||||
| Decrease / Increase in Cash | 469.1770 | 481.4670 | 990.7270 | 462.4280 | 2,868.1640 | ||||||
| Employees | 2,150 | 2,300 | 2,500 | 3,000 | 3,400 | ||||||
